MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ridinilazole

CAS No. : 308362-25-6

MCE 国际站：Ridinilazole

产品活性：Ridinilazole 是一种新型的抗菌剂，作用于 C. difficile，MIC 范围为 0.06-0.25 µg/mL (MIC₉₀=8 µg/mL)。

研究领域：Anti-infection

作用靶点：Bacterial

In Vitro: Ridinilazole is a novel antibacterial that does not appear to act through the classical pathways associated with antibiotics, such as inhibition of cell wall, protein, lipid, RNA or DNA synthesis. Ridinilazole may impair cell division. Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect. In susceptibility testing of 82 clinical isolates of C. difficile (including ribotype 027), Ridinilazole displays potent growth inhibition and has lower MICs [MIC range, 0.06-0.25 µg/mL; MIC for 90% of the organisms (MIC90), 0.125 µg/mL] than Metronidazole (MIC range, 0.125-8 µg/mL; MIC₉₀, 8 µg/mL) or Vancomycin (MIC range, 0.5-4 µg/mL; MIC₉₀, 2 µg/mL). Similarly, Ridinilazole is found to be more potent than Metronidazole or Vancomycin at inhibiting the growth of 50 ribotype-defined C. difficile strains. The activity of Ridinilazole against specific C. difficile ribotypes (including ribotypes 001, 002, 005, 014, 027, 054 and 106) is similar, with an MIC range of 0.06–0.5 µg/mL and an MIC₉₀ of 0.125 µg/mL. In addition, Ridinilazole is more active against 11 ribotype 027 strains than either Metronidazole or Vancomycin.

In Vivo: In a hamster model of CDI with a once-daily dosing regimen, Ridinilazole displays greater efficacy than Vancomycin both against non-epidemic and epidemic strains of C. difficile. Similar to the twice-daily dosing study, plasma levels of Ridinilazole are below the level of detection, whereas caecal Ridinilazole concentrations are well above the MIC, thus demonstrating the non-absorbable nature of Ridinilazole and minimal systemic exposure.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Antibacterial Compound Library  |  Anti-COVID-19 Compound Library  |  Children’s Drug Library  |  Myricetin 3-O-α-L-arabinopyranoside  |  (1R,2S,7R)-Sitafloxacin-d₄ hydrochloride  |  Nebacumab  |  Gepotidacin  |  Amycolatopsin A  |  Antibiotic A-33853  |  Estradiol hemihydrate  |  Sulbactam-d₂ sodium  |  Antimicrobial agent-5  |  NBTIs-IN-4  |  Proanthocyanidins  |  Anticancer agent 120  |  Azlocillin sodium salt  |  Antitubercular agent-13  |  Lenampicillin hydrochloride  |  PC58538  |  SPR206 acetate  |  Caracemide  |  Antimicrobial agent-10  |  Doxycycline calcium  |  Antibacterial agent 138  |  Staurosporine  |  Dihydrostreptomycin sulfate  |  Ciclopirox olamine  |  Rubropunctamine  |  Topoisomerase IV inhibitor 2  |  Psoracorylifol C  |  WX-081  |  SQ109  |  Ethyl Orsellinate

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。